| Methods |
RCT. Placebo controlled, crossover design.
Double‐blind.
Masking of assessors not stated. |
| Participants |
20 male and female patients
Inclusion criteria: Symptoms of urinary incontinence, frequency and uninhibited bladder contractions during cystometry.
Exclusion criteria: >100 ml residual urine, maximum flow rate <10ml/s, bacterial cystitis, treated with other anticholinergic drugs or anti‐Parkinsonism preparations. |
| Interventions |
Treatment 1: emepronium bromide 200mg tid.
Treatment 2: placebo.
2 x 4 week treatment period. Washout not stated. |
| Outcomes |
Urinary symptom questionnaire.
Patient preference for treatment.
Urodynamic parameters.
Adverse events.
Laboratory tests. |
| Notes |
Urodynamic parameters not detailed as no change.
Small numbers in study.
Adverse events unclear.
1 withdrawal.
No follow up.
Data not in useable form for this review.
Company support declared. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
